Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tamoxifen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 8/20 | 0.97 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.97 |
| ▸ | MAPT | P10636 | 3/20 | 0.97 |
| ▸ | MEN1 | O00255 | 3/20 | 0.97 |
| ▸ | TP53 | P04637 | 3/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.97 |
| ▸ | ESRRG | P62508 | 3/20 | 0.97 |
| ▸ | PGR | P06401 | 2/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.97 |
| ▸ | HTR6 | P50406 | 2/20 | 0.97 |
| ▸ | NPC1 | O15118 | 1/20 | 0.97 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.97 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.97 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.97 |
| ▸ | EGFR | P00533 | 1/20 | 0.97 |
| ▸ | GBA1 | P04062 | 1/20 | 0.97 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.97 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tamoxifen SCHEMBL4084 | 0.99 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL4085 | 0.99 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL119181 | 0.99 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL1056785 | 0.99 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL17262082 | 0.99 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| SCHEMBL29659348 | 0.99 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL17262111 | 0.99 | ESR1 (1.00) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL5789302 | 0.97 | ESR1 (0.97) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL4465197 | 0.97 | ESR1 (0.97) | ESR1ESR2MAPTMEN1TP53 | |
| Tamoxifen SCHEMBL17629803 | 0.97 | ESR1 (0.97) | ESR1ESR2MAPTMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785501-B2 | Anti-cancer tamoxifen-melatonin hybrid ligand | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785501-B2 | Anti-cancer tamoxifen-melatonin hybrid ligand | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130072539-A1 | Anti-Cancer Tamoxifen-Melatonin Hybrid Ligand | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2013-03-21 | — | — | US | disclosed |
| US-20130072539-A1 | Anti-Cancer Tamoxifen-Melatonin Hybrid Ligand | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2013-03-21 | — | — | US | disclosed |
| WO-2011046596-A3 | ANTI-CANCER TAMOXIFEN-MELATONIN HYBRID LIGAND | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT, A NONPROFIT CORPORATION ORGANIZED UNDER THE LAWS OF THE COMMONWEALTH OF PENNSYLVANIA (US) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011046596-A2 | ANTI-CANCER TAMOXIFEN-MELATONIN HYBRID LIGAND | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT, A NONPROFIT CORPORATION ORGANIZED UNDER THE LAWS OF THE COMMONWEALTH OF PENNSYLVANIA (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011046596-A2 | ANTI-CANCER TAMOXIFEN-MELATONIN HYBRID LIGAND | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT, A NONPROFIT CORPORATION ORGANIZED UNDER THE LAWS OF THE COMMONWEALTH OF PENNSYLVANIA (US) | 2011-04-21 | — | — | WO | disclosed |
| EP-1889639-A2 | Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents, for producing long lasting antineoplastic agents | ConjuChem Biotechnologies Inc. (CA) | 2008-02-20 | — | — | EP | disclosed |
| CN-1452498-A | pharmaceutically active compounds | NORGINE EUROPE BV (NL) | 2003-10-29 | — | — | CN | disclosed |
| EP-1212120-A2 | METHODS AND COMPOSITIONS CONTAINING SUCCINIMIDE OR MALEIMIDE DERIVATIVES OF ANTINEOPLASTIC AGENTS, FOR PRODUCING LONG LASTING ANTINEOPLASTIC AGENTS | Conjuchem, Inc. (CA) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001017614-A2 | METHODS AND COMPOSITIONS CONTAINING SUCCINIMIDE OR MALEIMIDE DERIVATIVES OF ANTINEOPLASTIC AGENTS | CONJUCHEM, INC. (CA) | 2001-03-15 | — | — | WO | disclosed |